Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 10 Breast Neoplasms 6 Triple Negative Breast Neoplasms 3 Sarcoma 3 Fallopian Tube Neoplasms 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 2 Breast Cancer Metastatic 2 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 SCLC, Extensive Stage 1 Recurrence 1 Platinum-sensitive Relapsed Ovarian Cancer 1 Osteosarcoma 1 Neoplasms 1 Nasopharyngeal Neoplasms 1 Nasopharyngeal Carcinoma 1 Kenny-Caffey syndrome, Type 1 1 Her-2 Negative Breast Cancer 1 Glioblastoma 1 Fludzoparib" and Anti-angiogenic 1 Female Breast Cancer Patients 1 Esophageal Squamous Cell Carcinoma 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Renal Cell 1 Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

fluzoparib 1 camrelizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Her-2 Negative Breast Cancer × fluzoparib × Clear all

NCT05761470 2023-03-09

IMPARP

First Affiliated Hospital, Sun Yat-Sen University

Phase 2 Recruiting

Her-2 Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡